Bay­er’s $425M non-hor­mon­al ther­a­py for menopause symp­toms clears first PhI­II test

The crown jew­el from Bay­er’s 2020 buy­out of women’s health biotech KaNDy Ther­a­peu­tics has proven its worth in the clin­ic, meet­ing all pri­ma­ry and sec­ondary end­points in a pair of Phase III stud­ies.

Bay­er says it plans to file the drug, elin­zane­tant, for reg­u­la­to­ry ap­provals to treat mod­er­ate to se­vere va­so­mo­tor symp­toms as­so­ci­at­ed with menopause once re­sults from a third Phase III study are in. Those da­ta are ex­pect­ed with­in the next few months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.